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Introduction {#sec1}
============

The vertebrate retina originates from the eye field, an anterior neural plate region identified by coexpression of a network of eye field transcription factors (EFTFs) including, among others, *Rax* and *Pax6* ([@bib34]).

In vertebrate embryos, downregulation of the bone morphogenetic protein (BMP) and Activin/Nodal signaling pathways is responsible for the specification of forebrain progenitors ([@bib1]). Anterior-posterior gradients of Wnts, fibroblast growth factors, and retinoic acid impose diencephalic, midbrain, hindbrain, or spinal cord identities on posteriorly located neural precursors. Rostral forebrain fates, instead, are preserved in anterior regions by shielding them from these signals ([@bib1], [@bib36]).

Although diversification of the secondary prosencephalon into telencephalon, eye field, and hypothalamus has been difficult to dissect in vivo, it can be modeled in vitro using mouse and human embryonic stem cells (mESCs and hESCs, respectively). In these culture systems, both endogenous and exogenous signals contribute to cell-fate specification. Previous reports have shown induction of hypothalamic fates by minimizing ESC exposure to exogenous signals ([@bib35]), whereas culture in minimal media in the presence of transforming growth factor β and Wnt pathway inhibitors causes telencephalic specification ([@bib3], [@bib21]). Extracellular cues, instead, appear to be critical for the induction of eye field fates, because production of retinal progenitors was generally inefficient in ESC systems with reduced extracellular signaling ([@bib21]).

Previous studies suggested that Activin/Nodal signaling promotes eye field fates, as shown by enhanced retinal progenitor generation in mESCs treated with exogenous Activin ([@bib14]) and by repression of eye field gene expression in hESCs differentiating in the presence of Activin/Nodal pathway inhibitors ([@bib20]). The contribution of Activin/Nodal signaling to eye field specification, however, remains poorly understood ([@bib21], [@bib34]). Here, building on previous studies ([@bib14], [@bib20]), we provide much more extensive evidence that Activin supports retinal identity in ESCs. Notably, we show that this function is restricted to a narrow time window coincident with the emergence of early forebrain progenitors from pluripotent cells. These findings suggest the feasibility of efficiently mimicking retinal progenitor formation in vitro using purely defined reagents.

Results {#sec2}
=======

Activin Supports Expression of Eye Field Genes in mESCs Differentiating to Anterior Neural Progenitors {#sec2.1}
------------------------------------------------------------------------------------------------------

We recently described a protocol of mESC neuralization using a chemically defined minimal medium (CDMM) ([@bib2]). mESCs are prompted to differentiate by floating aggregate culture (step I, 2 days) and then allowed to spontaneously neuralize as adherent cultures (step II, 4--6 days). In these conditions, mESCs efficiently convert to neural progenitors, which can undergo neuronal differentiation following long-term culture ([@bib2], [@bib3]).

With this protocol, we found that the endogenous levels of extracellular signaling pathways in early differentiating mESCs are permissive for neural conversion. Emerging neural progenitors, however, produce BMP and Wnt signals that repress rostral forebrain specification and promote caudal forebrain/midbrain fates ([@bib2], [@bib3]). Because BMP-dependent caudalization is, at least in part, indirectly due to activation of Wnt signaling, treatments with Wnt/β-catenin inhibitors during step II are sufficient to elicit rostral forebrain character in mESCs ([Figures 1](#fig1){ref-type="fig"}A--1C; [@bib3]). In this study, we used this experimental system and a *Rax*-GFP knockin mESC line (K/l EB5), driving eGFP expression under control of the *Rax* promoter ([@bib35]), to investigate the signals promoting eye field fates in early anterior neural progenitors. mESCs were differentiated to neuroectoderm with or without the Wnt/β-catenin signaling inhibitor IWR-1-Endo (Wnti) applied from 3 days of in vitro differentiation (3 DIV) ([Figure 1](#fig1){ref-type="fig"}A). Cells were harvested every 12 hr between 3.5 and 10 DIV, and GFP-positive cells were detected by flow cytometry or immunostaining. Cells treated with Wnti showed a transient activation of GFP expression between 5 and 6 DIV ([Figures 1](#fig1){ref-type="fig"}B and 1D). GFP-positive cells then decreased, reaching the very low numbers seen in control cultures by 8 DIV ([Figures 1](#fig1){ref-type="fig"}B and 1E). By quantitative RT-PCR (qRT-PCR), a peak of eye field marker (*Rax*, *Six6*) transcription was detectable at 5 DIV, but it rapidly declined ([Figure 1](#fig1){ref-type="fig"}C). Instead, telencephalic markers (*Emx2*, *FoxG1*, *Tbr1*, *Ctip2*) were steadily upregulated from 5 DIV onward ([Figure 1](#fig1){ref-type="fig"}C). Thus, differentiation in the presence of Wnt/β-catenin inhibitors converts mESCs to early forebrain progenitors that are competent to express both eye field and telencephalic genes. In the absence of appropriate signals, however, eye field gene transcription is not maintained and telencephalic fates prevail.

Previous work described repression of eye field genes in adherent hESC cultures differentiating in the presence of inhibitors of Activin/Nodal signaling ([@bib20]). Furthermore, exogenous Activin enhances generation of retinal progenitors in mESCs cultured as floating aggregates in serum-containing media ([@bib14]). Notably, bioinformatic analysis of chromatin immunoprecipitation sequencing datasets obtained in mouse and human ESCs indicate that both SMAD2/3 and FOXH1, key components of the Activin/Nodal pathway ([@bib38]), can bind to a highly conserved region located within 2 kb upstream of the *Rax* transcription start site ([Figure S1](#mmc1){ref-type="supplementary-material"}; [@bib17], [@bib25]). Thus, the instability of eye field gene transcription in our differentiation system may be due to insufficient activation of Activin/Nodal signaling.

mESCs differentiating to neuroectoderm with our protocol show very low expression of Activin/Nodal ligands, suggesting that Activin/Nodal signaling remains quiescent in these conditions ([@bib3]). Confirming these data, we found that *FoxH1* was barely expressed in either control differentiation conditions or in the presence of Wnti and/or the BMP pathway inhibitor dorsomorphin (BMPi) at 6 DIV but was upregulated by treatments with exogenous Activin (10--100 ng/ml; [Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). In these assays, weaker upregulation of *FoxH1* in the presence of BMPi ([Figure S2](#mmc1){ref-type="supplementary-material"}B) is likely due to the previously described partial interference of BMPi with the Activin/Nodal pathway ([@bib39]). As previously described ([@bib4]), high doses of Activin (50--100 ng/ml) also upregulated *Lefty1/2*, which encode for feedback inhibitors of Activin/Nodal signaling ([@bib23], [@bib28]), whereas genes encoding for other antagonists of this pathway (*Fst*; [@bib13]) were not affected ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

In support of the idea that Activin/Nodal signaling needs to be active for stable eye field gene transcription, simultaneous delivery of both Activin (10 ng/ml) and Wnti during mESC forebrain differentiation ([Figure 1](#fig1){ref-type="fig"}A; [Figure S1](#mmc1){ref-type="supplementary-material"}C) increased the fraction of *Rax*-GFP-positive cells at 8--10 DIV compared to cultures treated with Wnti alone ([Figures 1](#fig1){ref-type="fig"}B and 1D--1F). Costaining with PAX6 suggested that *Rax*-GFP-positive cells had a retinal progenitor identity ([Figures 1](#fig1){ref-type="fig"}G and 1G′). By qRT-PCR at 8 DIV, cultures treated with both Activin and Wnti showed upregulation of eye field markers (*Otx2*, *Six3*, *Rax*, *Six6*, *Tbx3*, *Vsx2*) and downregulation of telencephalic markers (*FoxG1*, *Emx2*, *Tbr1*, *Ctip2*) in comparison with Wnti-treated samples ([Figure 1](#fig1){ref-type="fig"}H).

In time course assays, the percentage of *Rax*-GFP-positive cells in Activin-treated cultures, compared to samples treated with Wnti only, was lower at 5--6 DIV and became similar at 6.5 DIV ([Figure 1](#fig1){ref-type="fig"}B). From 6.5 DIV, however, *Rax*-GFP-positive cells rapidly disappeared in Wnti-treated cultures, whereas their fraction progressively increased in the presence of Activin, nearly reaching 50% at 10 DIV ([Figure 1](#fig1){ref-type="fig"}B). Activin treatment delayed mESC neuralization, as shown by enhanced expression of the epiblast markers *Oct4* and *Fgf5* and repression of the neuroectoderm markers *Pax6* and *NCAM* at 6 DIV compared to controls ([Figure S2](#mmc1){ref-type="supplementary-material"}D), thus explaining the later appearance of *Rax*-GFP-positive cells in Activin-treated cultures. Nonetheless, *Oct4* and *Fgf5* were downregulated at 8 DIV ([Figure S2](#mmc1){ref-type="supplementary-material"}D) and neural progenitors expressing *Rax*-GFP, *Pax6*, and other eye field markers (e.g., *Six3*, *Six6*, *Tbx3*) became evident ([Figures S2](#mmc1){ref-type="supplementary-material"}E--S2H). Thus, low doses of Activin can transiently delay neural differentiation in mESCs but, once cells convert to neural progenitors, Activin signaling can steer them toward eye field fates.

We systematically analyzed the effects of Activin/Nodal signaling on neural induction and patterning in mESCs, starting by treating differentiating cells with exogenous Activin at different concentrations. We delivered Activin and Wnti simultaneously from 3 DIV using 10, 50, and 100 ng/ml Activin ([Figure S3](#mmc1){ref-type="supplementary-material"}). Activin caused dose-dependent inhibition of neural progenitor markers (*Sox2*, *Nestin*, *Pax6*, *Musashi*) and upregulation of pluripotency (*Oct4*, *Fgf5*) and mesendoderm (*Gata4*, *Gata6*) markers at 6 DIV ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3L). The ability of Activin to upregulate expression of eye field markers (*Otx2*, *Six3*, *Rax*, *Six6*, *Vsx2*, *Tbx3*) decreased at higher doses, consistent with a stronger inhibition of neural differentiation ([Figure S3](#mmc1){ref-type="supplementary-material"}M), whereas transcription of the telencephalic markers *Foxg1* and *Emx2* was always repressed ([Figure S3](#mmc1){ref-type="supplementary-material"}M). Activin delivery in the absence of Wnti caused a stronger upregulation of mesendoderm markers ([Figure S3](#mmc1){ref-type="supplementary-material"}B) and a weaker upregulation of eye field markers ([Figure S3](#mmc1){ref-type="supplementary-material"}M) in comparison with treatments with both Wnti and Activin, suggesting that Activin elicits eye field fates specifically in anterior neural progenitors, which form more efficiently when the Wnt/β-catenin pathway is inhibited ([@bib3]). The effects of Activin in the presence of both Wnti and BMPi were similar to those of treatments without BMPi ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3M), indicating that endogenous BMP signaling does not hinder eye field specification in this system. Treatments with the Activin/Nodal inhibitor SB431542 did not affect expression of eye field or telencephalic markers ([Figure S3](#mmc1){ref-type="supplementary-material"}N), in agreement with the very low endogenous activation of Activin/Nodal signaling in these conditions ([@bib3]). Although these data suggest that Activin can steer pluripotent stem cells differentiating to anterior neuroectoderm toward eye field fates, their interpretation is complicated by the fact that early Activin treatments, in line with previous studies ([@bib21], [@bib32]), interfere with mESC neuralization.

Activin Promotes Eye Field Fates within a Specific Time Window during Differentiation of mESCs to Anterior Neural Progenitors {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------------

To distinguish an earlier role of Activin/Nodal signaling in opposing neuroectoderm differentiation from a later role in anterior neural patterning, we focused on a moderate dose of Activin (10 ng/ml), which is more permissive toward mESC neuralization compared to higher doses ([Figures S2](#mmc1){ref-type="supplementary-material"}C and [S3](#mmc1){ref-type="supplementary-material"}), but started the treatments at different time points during anterior neural differentiation. Cultures were treated with Wnti from 3 DIV with or without Activin, which was added starting at the same time point or with increasing delays of 12, 24, 36, or 48 hr ([Figure 2](#fig2){ref-type="fig"}A); the percentage of the total cell count that was positive for *Rax*-GFP or OCT4 was then analyzed at 8 DIV. Cultures treated with Wnti alone differentiated efficiently to neuroectoderm (as shown by very few OCT4-positive cells), but they were refractory to eye field specification (5% *Rax*-GFP-positive cells; [Figures 2](#fig2){ref-type="fig"}B and 2C). When Activin was added together with Wnti (3 DIV), it promoted eye field specification (26.9% of *Rax*-GFP-positive cells; [Figures 2](#fig2){ref-type="fig"}B and 2D) but delayed neuroectoderm differentiation (18.9% of OCT4-positive cells persisting at 8 DIV; [Figures 2](#fig2){ref-type="fig"}B and 2D). Delaying the start of Activin treatment by 12--36 hr after Wnti delivery (3.5--4.5 DIV; [Figure 2](#fig2){ref-type="fig"}A) nearly doubled the percentage of *Rax*-GFP-positive cells (up to 45.2% *Rax*-GFP-positive cells at 8 DIV; [Figures 2](#fig2){ref-type="fig"}B--2G) without delaying differentiation (3% OCT4-positive cells at 8 DIV following Activin treatment from 4 DIV; [Figures 2](#fig2){ref-type="fig"}B--2G). No induction of *Rax*-GFP-positive cells was observed when cultures were treated with Activin starting from 5 DIV (5.5% *Rax*-GFP-positive cells at 8 DIV; [Figures 2](#fig2){ref-type="fig"}B and 2H). qRT-PCR analyses confirmed that transcription of *Six3*, *Rax*, *Six6*, and *Vsx2* peaked when Activin treatments were started between 12 and 36 hr after Wnti delivery ([Figure 2](#fig2){ref-type="fig"}I) but was similar to control (Wnt inhibition alone) levels when applying Activin 48 hr after Wnti ([Figure 2](#fig2){ref-type="fig"}I).

Activin treatment conditions causing optimal upregulation of eye field genes were also more effective at downregulating expression of telencephalic markers ([Figure 2](#fig2){ref-type="fig"}I). Activin efficiently enhanced eye field gene expression only in cultures treated with Wnti ([Figures 2](#fig2){ref-type="fig"}B and 2I), supporting the idea that Activin promotes eye field fates in anterior neural progenitors.

Higher Activin doses (50 ng/ml), even when delivered at 3.5 DIV ([Figure S4](#mmc1){ref-type="supplementary-material"}A), decreased the fraction of *Rax*-GFP-positive cells at 8 DIV, probably due to maintenance of *Oct4* expression and delayed neuroectoderm differentiation ([Figures S4](#mmc1){ref-type="supplementary-material"}B--S4M). Altogether, these results suggest that Activin plays different roles at different stages of mESC differentiation. At early stages (up to 3 DIV), Activin opposes neuroectoderm specification by promoting expression of pluripotency and mesendoderm genes. In early anterior neural progenitors, which emerge at 3.5--4.5 DIV in conditions of low Wnt signaling, moderate Activin levels promote eye field fates.

Activin Promotes Formation of *Rax*-Expressing Progenitors Bearing Retinal-Specific Regional Identities {#sec2.3}
-------------------------------------------------------------------------------------------------------

In mouse embryos, strong *Rax* expression is found both in the developing retina and ventral hypothalamus ([@bib35]). Retinal progenitors express *Rax* and *Pax6*, whereas ventral hypothalamic progenitors express *Rax* and *Nkx2.1* ([@bib14], [@bib36]). Because Wnt inhibition and Activin/Nodal signaling have been implicated in hypothalamic development ([@bib16], [@bib22]), we investigated whether *Rax*-expressing progenitors generated in the presence of Wnti and Activin acquired retinal and/or hypothalamic identities. Sonic Hedgehog (SHH) signaling has a well-established role in promoting hypothalamic development ([@bib14], [@bib35]). Therefore, to better distinguish *Rax*-positive retinal fates from *Rax*-positive hypothalamic fates, we compared the identity of *Rax*-expressing progenitors forming in Activin-treated cultures with that of *Rax*-positive cells generated in cultures treated with SHH pathway agonists.

*Rax*-GFP-positive progenitors induced by treating differentiating mESC cultures with both Wnti (from 3 DIV) and Activin (from 3.5 DIV) were mostly PAX6 positive and NKX2.1 negative at 8 DIV (up to 40.7% *Rax*-GFP-positive cells, 32.4% *Rax*-GFP/PAX6 double-positive cells, 2.2% *Rax*-GFP/NKX2.1 double-positive cells; [Figure 3](#fig3){ref-type="fig"}), suggesting that they had acquired a retinal identity.

Previous studies indicated that activation of SHH signaling in mESCs differentiating to anterior neuroectoderm led to the specification of ventral hypothalamic progenitors expressing *Rax* and *Nkx2.1* ([@bib35]). To further confirm that *Rax*-positive cells generated in Activin-treated cultures acquired a retinal, rather than hypothalamic, identity, we generated *Rax*-positive ventral forebrain progenitors by means of treatments with a Smoothened agonist (SAG; 100 nM). SAG was added to differentiating mESC cultures from 3 DIV with or without Wnti. Some of these cultures were also treated with Activin from 3.5 DIV ([Figure 3](#fig3){ref-type="fig"}A). SAG robustly increased the percentage of *Rax*-GFP-positive cells (up to 61.6% of the total cell count) at 8 DIV, but only in cultures treated with Wnti ([Figures 3](#fig3){ref-type="fig"}B--3D). In contrast to Activin treatments, however, the vast majority of these cells were PAX6 negative and NKX2.1 positive (0.6% *Rax*-GFP/PAX6 double-positive cells, 60% *Rax*-GFP/NKX2.1 double-positive cells; [Figures 3](#fig3){ref-type="fig"}B and 3D), indicating acquisition of a ventral hypothalamic identity. NKX2.1-expressing cells were increased by SAG also in the absence of Wnti (65.3% NKX2.1-positive cells), but they were mostly *Rax*-GFP negative ([Figures 3](#fig3){ref-type="fig"}B and 3C). Activin and SAG treatments together did not show collaborative effects in the generation of *Rax*-GFP-positive cells, which were mostly PAX6 negative and NKX2.1 positive ([Figures 3](#fig3){ref-type="fig"}B--3D). Similar results were obtained when cultures were treated with Activin and different doses of SAG (1, 10, 100 nM; [Figures S5](#mmc1){ref-type="supplementary-material"}A--S5D). Inhibition of SHH signaling with cyclopamine (5 μM) in cultures treated with Activin did not enhance either the generation of *Rax*-GFP-positive cells or the fraction of cells coexpressing *Rax*-GFP and PAX6 ([Figures 3](#fig3){ref-type="fig"}B--3D), in agreement with the observation that endogenous SHH signaling is inactive during the early stages of our differentiation protocol ([@bib3]).

Treatments with Wnti and Activin could promote formation of *Rax*-GFP/PAX6-positive (NKX2.1-negative) retinal progenitors even when cells were maintained as floating aggregates until harvesting at 10 DIV ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F). Treatments of floating aggregate cultures with Wnti and SAG led to formation of *Rax*-GFP/NKX2.1-positive (PAX6-negative) progenitors. Retinal progenitors were mainly present within superficial layers of Activin-treated cell aggregates, whereas hypothalamic progenitors could be found throughout SAG-treated aggregates. This may be explained by more limited diffusion of exogenous signaling proteins (as compared to small molecules) within cell aggregates.

We further characterized the positional identity of adherent cultures treated with either Wnti and Activin or Wnti and SAG by global transcriptomic analyses. We sorted *Rax*-positive (*Rax*^+^) or *Rax*-negative (*Rax*^−^) cells from these cultures at 10 DIV ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6E) and used them, along with unsorted cells from cultures treated only with Wnti, for microarray-based comparative gene expression profiling with respect to eye, cortex, or hypothalamus/diencephalon explanted from embryonic day 12.5 mouse embryos ([Figure 4](#fig4){ref-type="fig"}; [Figures S6](#mmc1){ref-type="supplementary-material"}F--S6H). Pearson correlation analysis indicated that cell cultures and embryonic tissues clustered separately, with high values of correlation among samples of the same category ([Figure S6](#mmc1){ref-type="supplementary-material"}F). Principal component analysis (PCA) confirmed that cultures and tissues formed well-separated groups ([Figure S6](#mmc1){ref-type="supplementary-material"}G). Moreover, it indicated that the large majority of genes whose expression varies among different samples (principal component 1, accounting for 92.7% of variance) is actually not separating them and that only a small ratio of gene expression variance (principal component 2, accounting for 2.2% of variance) is responsible for the difference between cell-culture sample and tissue sample groups ([Figure S6](#mmc1){ref-type="supplementary-material"}G). These analyses suggested that the genes whose expression accounts for differences among different brain regions, and different cell-culture conditions, are few, and that the variance of their expression is masked by the variance of the rest of the genes. We then performed clustering and PCA on a transcriptome subset, including genes with highest variance among tissues or cultures (see the [Experimental Procedures](#sec4){ref-type="sec"}). Analysis of this subset indicated that cells treated with Wnti and Activin clustered with embryonic eye tissue and cells treated with Wnti and SAG clustered with embryonic hypothalamus/diencephalon, whereas control cultures treated with Wnti only clustered with embryonic cortex ([Figures 4](#fig4){ref-type="fig"}A and 4B). Notably, the values of correlation among samples of the same category (cell culture or tissue) were quite low, indicating that this subset of genes can discriminate different positional identities in both cell culture and tissue samples, regardless of their in vitro or in vivo origin ([Figure 4](#fig4){ref-type="fig"}A). Accordingly, the first two principal components of the PCA, together accounting for 49.8% and 19.3% of variance, respectively, divided the samples into the same three major clusters (corresponding to eye, hypothalamus/diencephalon, and cortex identities) identified by Pearson correlation analysis ([Figure 4](#fig4){ref-type="fig"}B). Unexpectedly, neither analysis was able to neatly separate *Rax*^+^ from *Rax*^−^ cells in cultures treated with Activin or SAG. A closer inspection of each transcriptome contributed to explaining why *Rax*^+^ and *Rax*^−^ cells seemed more homogeneous than expected when compared to embryonic tissues. In cultures treated with Activin, *Rax*^−^ cells expressed higher levels of both epiblast and endo/mesoderm markers in comparison to *Rax*^+^ cells but also appreciable levels of retinal markers, including *Rax*. This suggests that a fraction of these cells had activated *Rax* expression and started retinal differentiation, even if they had not yet accumulated enough GFP fluorescence, and that the ratio of GFP-positive cells at DIV 10 represents an underestimation of the fraction of cells with a retinal gene expression profile. In cultures treated with SAG, both *Rax*^+^ and *Rax*^−^ cells expressed a substantial number of hypothalamic and prethalamic markers ([Figure 4](#fig4){ref-type="fig"}C and data not shown). We then extrapolated small subsets of markers that identify distinct hypothalamic and/or prethalamic regions, as previously described ([@bib29]; [Figure 4](#fig4){ref-type="fig"}C; [Figure S6](#mmc1){ref-type="supplementary-material"}H). This analysis indicated that *Rax*^+^ cells preferentially express markers of ventral hypothalamic regions, whereas *Rax*^−^ cells tend to express markers of more dorsal hypothalamic regions or prethalamic areas ([Figure 4](#fig4){ref-type="fig"}D), in agreement with the distribution of *Rax* expression in the developing hypothalamus and diencephalon ([@bib35]).

Our results suggest that both Activin and SHH signaling are able to drive *Rax* expression in early anterior neural progenitors, but that they work independently of each other promoting alternative cell fates. Different from SHH signaling, Activin supports formation of retinal progenitors coexpressing *Rax* and PAX6, rather than *Rax*-NKX2.1-positive ventral hypothalamic progenitors. To further support these conclusions, we evaluated the ability of *Rax*^+^ progenitors induced by Activin or SAG treatments to undertake a retinal neuron differentiation program in long-term cultures (up to 22 DIV; [Figure 5](#fig5){ref-type="fig"}A). Besides *Rax*, cells treated with Wnti and Activin (10 ng/ml, 12-hr delayed treatment), but not SAG, transcribed *Crx*, a marker of immature photoreceptor cells, *Vsx2*, a marker of differentiating bipolar cells, and *Brn3b*, a marker of differentiating retinal ganglion cells, at 18--22 DIV ([Figure 5](#fig5){ref-type="fig"}B; [Figure S7](#mmc1){ref-type="supplementary-material"}F). At 22 DIV, cells positive for Rhodopsin, a marker of more mature photoreceptors, were evident in these cultures ([Figures 5](#fig5){ref-type="fig"}D and 5E) but not in control or SAG-treated cultures (data not shown). Rhodopsin-positive cells were preferentially located in close proximity to clusters of *Rax*-GFP-positive retinal progenitors, but they showed weak *Rax*-GFP signal themselves ([Figures 5](#fig5){ref-type="fig"}D and 5E). This is consistent with the fact that retinal progenitors switch off *Rax* expression when they undergo terminal differentiation ([@bib10], [@bib11]). In contrast, SAG-treated long-term cultures produced GAD65-positive neurons (27.6%; [Figure 5](#fig5){ref-type="fig"}F). At 22 DIV, cells treated with both Wnti and Activin also upregulated other markers of retinal neuron differentiation in comparison with Wnti-treated samples. In addition to Rhodopsin, Cone Opsin (cones), BRN3 (ganglion cells), VSX2 (bipolar cells), and Recoverin (pan-photoreceptor) were detected in significant percentages of cells ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7E and S7G). These results suggest that *Rax*-expressing progenitors generated in the presence of Activin mainly acquire a retinal identity, which can be distinguished from SHH-dependent hypothalamic fates.

Activin Promotes Eye Field Gene Expression in Differentiating hESCs {#sec2.4}
-------------------------------------------------------------------

Culture of hESCs as floating aggregates in a chemically defined minimal medium (CDMM) ([@bib32]) is permissive, to some extent, for differentiation to neural progenitors expressing early anterior neural markers such as *OTX2* and *PAX6* ([@bib27], [@bib30], [@bib32]). We therefore used this straightforward experimental system to address whether Activin treatments could promote eye field gene expression in differentiating hESCs. hESCs were differentiated as floating aggregates for 12--14 days in basic CDMM or CDMM supplemented with 50 ng/ml Activin. These doses of Activin were chosen to compensate for limited diffusion of exogenous growth factors within hESC aggregates, as previously described ([@bib32]). Cell aggregates were then harvested for molecular marker analyses by in situ hybridization and qRT-PCR. As detected by in situ hybridization, Activin treatments increased the number of *OCT4*-positive aggregates, although the majority of the aggregates were *OCT4* negative ([Figure 6](#fig6){ref-type="fig"}A). Thus, Activin could delay, but not prevent, hESC differentiation in these conditions. Nonetheless, compared with controls, Activin-treated cultures showed stronger expression of eye field markers (*OTX2*, *RAX*, *VSX2*, *PAX6*), but not of the telencephalic marker *FOXG1*, both in terms of percentage of positive aggregates and staining intensity ([Figure 6](#fig6){ref-type="fig"}A). qRT-PCR analysis confirmed a significant increase in transcription levels of several eye field markers (*RAX*, *VSX2*, *SIX6*, *OTX2*, *LHX2*, *PAX6*) following Activin treatments, whereas telencephalic markers (*OTX1*, *FOXG1*) were not significantly affected ([Figure 6](#fig6){ref-type="fig"}B). These data suggest that Activin can support the expression of eye field genes during differentiation of both mESCs and hESCs.

Discussion {#sec3}
==========

The extracellular signals that induce the EFTF network in retinal progenitors are poorly understood. Although inhibition of BMP and Wnt/β-catenin signaling has been implicated in eye field formation ([@bib7], [@bib18]), transient downregulation of these pathways appears to be a prerequisite for the initial specification of the entire secondary prosencephalon. How the telencephalon, eye field, and hypothalamus are then diversified within this prosencephalic tissue remains unclear.

In ESC in vitro systems, culture conditions devoid of exogenous signals or supplemented with inhibitors of endogenous signals were not sufficient for efficient generation of retinal progenitors and they drove instead hypothalamic or telencephalic specification ([@bib3], [@bib20], [@bib26], [@bib35]). To date, efficient acquisition of retinal identity has been achieved via poorly defined exogenous cues, including complex extracellular matrices (ECMs) and biological supplements ([@bib21], [@bib34], [@bib5], [@bib8], [@bib12], [@bib40]).

Previous work suggested that Activin/Nodal signaling promotes eye field fates in ESCs. In particular, supplementation of serum and serum replacement media with Activin increased the production of retinal progenitors from mESCs ([@bib14]). Subsequently, a combination of the Nodal and ECM molecules entactin and laminin was found to mimic retinal progenitor induction by Matrigel ([@bib8]). Finally, inhibitors of the Activin/Nodal pathway repressed eye field gene expression during neuroectoderm differentiation of hESCs ([@bib20]). These studies, however, did not clarify the role of Activin/Nodal signaling in retinal progenitor specification.

In this study, we show that Activin promotes eye field fates in mESCs differentiating to anterior neuroectoderm in chemically defined minimal media. Activin effectively upregulated eye field gene expression only when delivered at moderate doses and within a narrow 24-hr time window during early steps of neuroectoderm differentiation. In agreement with previous literature ([@bib21], [@bib30], [@bib32]), treatments at higher doses and/or earlier time points promoted pluripotency and mesendoderm differentiation and repressed neuroectoderm differentiation, whereas later treatments could not support retinal identity. Moreover, Activin efficiently enhanced eye field specification only in cultures treated with inhibitors of Wnt/β-catenin signaling, which promote anterior neural fates at the expense of posterior fates in differentiating ESCs ([@bib2], [@bib20], [@bib21], [@bib26]). Hence, the effects of Activin are dependent on the competence of the responding cells: we speculate that Activin can upregulate eye field genes in primitive forebrain progenitors, but not in pluripotent cells, later forebrain progenitors, or posterior neural progenitors. We observed Activin-dependent upregulation of eye field genes in either adherent or floating aggregate cultures. Activin enhanced eye field gene expression also in hESCs differentiating as floating aggregates in chemically defined medium devoid of ECM components and serum replacement, indicating that the ability of Activin to promote eye field fates is not limited to mouse ESCs or to a specific cell line or culture method.

In mouse embryos, both the developing retina and the ventral hypothalamus show strong *Rax* expression ([@bib14], [@bib35], [@bib36]). Consistent with previous studies ([@bib14], [@bib35]), we confirmed that SHH agonists upregulated *Rax* in mESCs but in the context of ventral hypothalamic specification, because *Rax*-expressing cells were positive for NKX2.1 and negative for PAX6. Upon terminal differentiation, these cultures generated GAD65-positive neurons. Side-by-side comparison of Activin and SAG treatments confirmed that the effects of these molecules were clearly distinguishable. Activin, but not SAG, supported specification of *Rax*-PAX6-positive retinal progenitors, which were endowed with transcriptomic profiles clustering with those of embryonic eye tissue and were capable of undertaking retinal neuron differentiation in long-term cultures.

Activin/Nodal signaling controls early vertebrate development at multiple levels, and it is difficult to distinguish direct roles in eye development from indirect effects. Forebrain and eye formation are affected in fish and mouse mutants with defective Activin/Nodal signaling ([@bib19], [@bib33], [@bib36]), but these effects are likely due to the disruption of mesendodermal signaling centers required for rostral neuroectoderm formation ([@bib36]). Excessive Activin/Nodal signaling, however, can repress anterior neural fates by maintaining pluripotency and/or promoting mesendoderm differentiation within the ectoderm ([@bib31], [@bib32]). Anterior neural induction occurs prematurely in the epiblast of *Nodal* mouse mutants ([@bib6]), but although telencephalic genes are upregulated in Nodal-deficient anterior neuroectoderm, eye field markers (*Six3* and *Pax6*) are not properly expressed ([@bib6]). Furthermore, during eye morphogenesis, eye field cells migrating laterally to form the optic vesicles become exposed to Activin-like signals released by extraocular tissues. Although these signals are involved in retinal pigment epithelium and anterior eye segment specification ([@bib9], [@bib15]), they might also support retinal progenitor identity. Highlighting the complex functions of Activin/Nodal signaling in eye development, recent studies in *Xenopus* found opposite effects of Nodal signaling inhibition on the specification of retinal identity using different experimental assays ([@bib24], [@bib37]). Clearly, the roles of Activin/Nodal signaling in eye formation are much more difficult to dissect in vivo than they are in vitro, and further investigations in animal model organisms are warranted.

The results described in this and previous studies using ESC in vitro systems ([@bib2], [@bib3], [@bib20], [@bib21]) lead to a model of the role of the Activin/Nodal pathway in the specification of retinal identity ([Figure 7](#fig7){ref-type="fig"}). In this model, downregulation of Activin/Nodal signaling in pluripotent cells leads to the emergence of early anterior neural progenitors, which can acquire rostral forebrain fates (corresponding to progenitors of the secondary prosencephalon in vivo) or caudal forebrain fates (corresponding to progenitors of the diencephalic/mesencephalic regions in vivo) depending on the levels of Wnt/β-catenin signaling, as previously described ([@bib21] and references therein). Without further signaling, primitive rostral forebrain progenitors spontaneously evolve toward a default cortical identity ([@bib2], [@bib21]), whereas they can be steered to retinal fates under the influence of Activin. As in previous studies ([@bib14], [@bib35]), SHH signaling instead promotes ventral hypothalamic fates. Although more work is needed to address the function of Activin/Nodal signals during early eye development in vivo, this model provides a framework for future studies aimed at clarifying the mechanisms of eye field formation and producing retinal progenitors for basic research or therapy.

Experimental Procedures {#sec4}
=======================

Murine ESC lines E14Tg2A (passages 25--38) and K/l EB5 (transgenic Rax-GFP ESCs, used with the kind permission of Y. Sasai, RIKEN Center) and H9 hESCs (WiCell) were cultured as described ([@bib2], [@bib20]). All animal protocols were reviewed and approved by the Animal Protocol Review Committee at ITB-CNR of Pisa.

Detailed experimental procedures are available in [Supplemental Information](#app3){ref-type="sec"}.

Accession Numbers {#app1}
=================

The accession number for the microarray gene expression data reported in this paper is GEO: [GSE71830](ncbi-geo:GSE71830){#intref0010}.
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![Activin Supports *Rax* Expression in mESC-Derived Early Anterior Neural Progenitors\
(A) Scheme of mESC neuroectoderm differentiation with or without Wnti and Activin. Days show the time of mouse ESC differentiation after LIF (−LIF) and serum withdrawal.\
(B) Flow cytometry of K/l EB5 cells harvested at different time points showing the percentage of *Rax*-GFP-positive cells during differentiation in plain CDMM (control) or in the presence of Wnti or Wnti and Activin (Wnti+Act), as indicated. Error bars represent SEM (n = 4 independent experiments with n = 3 in vitro technical replicates per experiment; technical replicates were pooled together and analyzed by n = 3 flow cytometry acquisitions).\
(C) qRT-PCR quantification of telencephalic (*Emx2*, *FoxG1*, *Tbr1*, *Ctip2*) and eye field (*Rax*, *Six6*) gene expression in cells differentiated in the presence of Wnti and harvested every 24 hr between 4 and 8 DIV. For each analyzed gene, the sample with maximal transcription levels was chosen for normalization, and relative expression levels in all the other samples are shown. Error bars were obtained from the error propagation formula (n = 3 independent biological replicates were pooled together and analyzed by qRT-PCR).\
(D--F) GFP immunodetection of cells differentiated in the presence of Wnti or Wnti and Activin (Wnti/Act.). The scale bars represent 50 μm. Dapi, 4′,6-diamidino-2-phenylindole.\
(G and G′) Double immunodetection at 8 DIV in cultures treated with Wnti and Activin. The scale bar represents 10 μm.\
(H) qRT-PCR of mesencephalic (*En1*, *Otx2*), telencephalic (*Emx2*, *FoxG1*, *Ctip2*, *Tbr1*), and eye field (*Rax*, *Six6*, *Vsx2*, *Six3*, *Otx2*, *Tbx3*) marker expression at 8 DIV in cultures differentiated in control medium (CDMM) or in medium supplemented with Wnti (Wnti) or both Wnti and Activin (10 ng/ml; Wnti+Act). Error bars were obtained from the error propagation formula (n = 3 independent experiments were pooled together and analyzed by qRT-PCR; each experiment contained n = 2 in vitro technical replicates).\
See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Activin Promotes *Rax* Expression within a Restricted Time Window during mESC Differentiation to Anterior Neuroectoderm\
(A) Scheme of temporally controlled Activin treatments.\
(B) Percentage of the total K/l EB5 cell count that was positive for OCT4 or *Rax*-GFP. Culture conditions were as in (A). Ctrl, control (CDMM). Error bars represent SEM (n = 3 independent experiments).\
(C--H) Representative images of K/l EB5 cells differentiated in the conditions indicated in (A) and immunostained for both GFP and OCT4 at 8 DIV. The scale bars represent 50 μm.\
(I) qRT-PCR of neuroectoderm (*Pax6*), telencephalic (*Tbr1*, *Emx2*, *FoxG1*), and eye field (*Six3*, *Rax*, *Six6*, *Vsx2*) gene expression in the conditions indicated in (A). Values are normalized to samples with maximal expression levels. Error bars were obtained from the error propagation formula (n = 3 independent experiments were pooled together; each experiment contained n = 2 technical replicates).\
See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Activin and SHH Signaling Promote Retinal Progenitor or Ventral Forebrain Progenitor Identity, Respectively, in mESCs Differentiating to Anterior Neuroectoderm\
(A) Scheme of anterior neural differentiation of mESCs in the presence of different signaling molecules. Activin was applied 12 hr after the start of Wnti treatments, whereas SAG or cyclopamine (Cyc) was delivered simultaneously with Wnti.\
(B) Quantification of the percentage of the total K/l EB5 cell count that was positive for *Rax*-GFP and/or PAX6 (left chart) or for *Rax*-GFP and/or NKX2.1 (right chart), as detected by immunodetection at 8 DIV, following differentiation in the indicated conditions. Error bars represent SEM (n = 3 independent experiments).\
(C and D) Representative images of K/l EB5 cells differentiated in the indicated conditions at 8 DIV. The scale bars represent 30 μm.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Cultures Treated with Activin or SAG Display Eye or Hypothalamic/Diencephalic Gene Expression Profiles, Respectively\
(A) Clustering analysis, showing the distribution of Pearson correlation among transcriptome subsets of different cell cultures and embryonic brain regions. The subset of transcriptome analyzed consists of the 414 gene with the highest variance among cell cultures or tissues (top 2%; see the [Experimental Procedures](#sec4){ref-type="sec"}). Hyp/Die, hypothalamus/diencephalon; SAG, SHH agonist; *Rax*^+^ and *Rax*^−^, K/l EB5 cells positive or negative for GFP expression, respectively; Wi, Wnt inhibition; Ctx, cortex; Act, Activin.\
(B) PCA of samples as in (A). PC1 and PC2 indicate the first and second principal component, respectively, with percentages of explained variance in parentheses.\
(C) Color heatmap showing log~2~ mean normalized expression of selected gene subsets, marking retina (RET), epiblast (EPI), or endomesoderm (E/M) cell identity in Activin-treated *Rax*^+^ and *Rax*^−^ cells.\
(D) Color heatmap showing log~2~ mean normalized expression of selected gene subsets in SAG-treated *Rax*^+^ and *Rax*^−^ cells. Each gene subset marks a specific prethalamic (purple and dark brown) or hypothalamic (other colors) region, as described in [@bib29].\
(E) Color heatmap showing the log~2~ fold change (FC) ratio of the mean normalized expression values in (D). SMM, supramamillary nucleus; MM, mamillary nucleus; PM, premamillary region; VMH, ventromedial hypothalamic nucleus; ARC arcuate nucleus; ID, intrahypothalamic diagonal region; TT, tuberomamillary terminal region; PVN, paraventricular nucleus; EmThal, eminentia thalami; PTh, prethalamus; vAH, ventral anterior hypothalamus. Tissue samples were obtained from n = 3 embryos (wild-type, Sv129s6 mouse strain, Taconic) and pooled together before RNA extraction. In vitro samples were produced with n = 3 technical replicates; cells were dissociated and pooled together before processing.\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Terminal Differentiation of Activin-Treated Cells or SAG-Treated Cells Generates Rhodopsin-Positive Neurons or Gad65-Positive Neurons, Respectively\
(A) Scheme of long-term mESC differentiation in the presence of Wnti and Activin (Wnti/Act), with or without Cyc, or with Wnti and SAG (Wnti/SAG). Activin and SAG were applied 12 hr after the start of Wnti treatments, whereas Cyc was delivered simultaneously with Wnti.\
(B) qRT-PCR of retinal marker (*Rax*, *Crx*, *Vsx2*) expression 18 DIV. Results are normalized to samples with maximal expression levels for each marker. Error bars were obtained from the error propagation formula (n = 3 independent experiments).\
(C--F) Representative images of K/l EB5 cells differentiated in the indicated conditions at 22 DIV. Rhodopsin-positive cells are indicated by arrowheads in (E). Gad65-positive neurons (27.6% GAD65-positive cells among B-III-Tub-positive neurons) are indicated by arrowheads in (F). The boxed area in (D) is shown at higher magnification in (E). The scale bars represent 30 μm (C and D), 10 μm (E), and 15 μm (F).\
See also [Figure S7](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Activin Promotes Eye Field Gene Expression in Differentiating hESCs\
(A) In situ hybridization on floating aggregates obtained following a 12-day differentiation of hESCs in nonadherent conditions either in plain CDMM or in the presence of Activin, as indicated. Arrowheads point to *RAX*-positive or *VSX2*-positive aggregates. Bar histograms show the percentage of aggregates displaying strong (dark purple), weak (light blue), or absent (white) signal. The scale bars represent 0.8 mm. Error bars represent SEM. (At least 100 aggregates for each culture condition and probe from one representative experiment were used for these analyses.) hEBs, human embryoid bodies.\
(B) qRT-PCR of gene expression in hESCs differentiated as floating aggregates for 12--14 days with or without Activin. Results are shown as the mean ratio between Activin and control conditions. Error bars represent SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ns, nonsignificant (p ≥ 0.05) according to Student's t test performed between Activin and control conditions (n = 8 independent experiments).](gr6){#fig6}

![Model of the Roles of the Activin/Nodal, Wnt/β-Catenin, and SHH Signaling Pathways in the Induction of Rostral Forebrain Precursors\
Embryonic structures and stages of mouse development in vivo corresponding to the progressively more fate-restricted progenitors emerging during ESC differentiation in vitro are shown. See text for details.](gr7){#fig7}
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